BMS: Sales For Opdivo Are Flying High
This article was originally published in Scrip
Recent approvals for Bristol-Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) resulted in accelerated sales in the second half, with rapid adoption in new indications, said CEO Giovanni Caforio at the J.P. Morgan conference in San Francisco this week.
You may also be interested in...
Bristol-Myers Squibb Co. is moving up the timing on its eagerly awaited CheckMate-026 first-line lung cancer trial of Opdivo, with data now expected in the third quarter – earlier than prior guidance.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.